Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adalvo and AmbioPharm Partner on Development & Licensing for Key Peptide Product","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adalvo Announces Successful DCP Closure for Icatibant","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Adalvo","sponsor":"Adalvo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adalvo Acquires Its First Branded Product, Onsolis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Adalvo","sponsor":"Zentiva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Adalvo","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz To Exclusively Commercialize Six Products In The Us, Reinforcing Global Leadership Position In Off-patent Medicines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Undisclosed","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Adalvo","sponsor":"Adamed Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adalvo and Adamed Pharma Team up to Launch Solifenacin + Tamsulosin in Europe","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Urology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Adalvo

    Menu

    Adalvo

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Adalvo

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adalvo and Adamed Pharma Team up to Launch Solifenacin + Tamsulosin in Europe

              Details:

              Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.

              Lead Product(s): Solifenacin Succinate,Tamsulosin

              Therapeutic Area: Urology Product Name: Vesomni-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Adamed Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adalvo

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sandoz To Exclusively Commercialize Six Products In The Us, Reinforcing Global Leadership Position In Off-patent Medicines

              Details:

              Under the agreement, Sandoz will get the rights to commercialize six products in the US across key therapeutic areas, including antifungal/antibiotic, oncology and pulmonary.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Sandoz B2B

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adalvo

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology

              Details:

              Under the terms of collaboration, Zentiva will complement their product offering with the support of longstanding partners Adalvo with new molecules in a variety of therapeutical areas like Respiratory, CNS and Dermatology.

              Lead Product(s): Undisclosed

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Zentiva

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Expanded Collaboration January 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adalvo

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adalvo Acquires Its First Branded Product, Onsolis

              Details:

              Adalvo will be the sole and exclusive owner of the Onsolis® (fentanyl) and will obtain full rights on the product, taking over all existing business and all market authorizations, globally, including the US.

              Lead Product(s): Fentanyl

              Therapeutic Area: Neurology Product Name: Onsolis

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Undisclosed

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition August 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adalvo

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adalvo Announces Successful DCP Closure for Icatibant

              Details:

              Icatibant, a complex injectable peptide product, forming part of high-value product, is an equivalent and more affordable version of Firazyr (Takeda/Shire), used used to treat a serious orphan disease, acute attacks of hereditary angioedema.

              Lead Product(s): Icatibant Acetate

              Therapeutic Area: Genetic Disease Product Name: Icatibant Acetate-Generic

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: AmbioPharm

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adalvo

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adalvo and AmbioPharm Partner on Development & Licensing for Key Peptide Product

              Details:

              The partnership includes a basket of difficult-to-make peptide products that will be used to treat various diseases, ranging from diabetes to immunology disorders, cardiologic and endocrinology diseases.

              Lead Product(s): Undisclosed

              Therapeutic Area: Endocrinology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Peptide

              Partner/Sponsor/Collaborator: AmbioPharm

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY